# A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors

> **NCT01624467** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 75 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **BIOLOGICAL:** Necitumumab

## Key facts

- **NCT ID:** NCT01624467
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2014-05
- **Final completion:** 2015-06
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2016-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624467, "A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01624467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*